COLOGNE, Germany, May 3, 2016 /PRNewswire/ -- Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling ...
Munich, Germany, June 25, 2009 --(PR.com)-- Stem cell derived cardiomyocytes have tremendous potential for cardiac safety testing of drug candidates. By offering an authentic cellular environment they ...
COLOGNE, Germany--(BUSINESS WIRE)--Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which ...
ST. LOUIS, July 31, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, has ...
Axiogenesis AG and Metrion Biosciences Ltd have signed a collaboration agreement to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately ...
GOSSELIES,Belgium & COLOGNE, Germany & LEIDEN, Netherlands & PHILADELPHIA--(BUSINESS WIRE)--Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The ...
Nanion and Axiogenesis present parallel patch clamp recordings of action potentials from Cor.At cardiomyocytes Stem cell derived cardiomyocytes were analyzed using Nanion’s automated patch clamp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results